In colorectal cancer cell lines, CBD showed much stronger cytotoxic effects and gene expression changes than its precursor CBDA, though a CBDA-rich cannabis extract outperformed a pure CBDA/CBD mixture — suggesting other plant compounds may enhance anti-cancer activity.
Cancer researchers, cannabinoid scientists, oncologists interested in adjunctive therapies, and anyone following cannabis and cancer research.
What the researchers found
CBD exhibited the strongest cytotoxic effect in both CRC cell lines (HCT116 IC50=9.87 μM; HT29 IC50=17.11 μM), while CBDA showed minimal toxicity. Notably, a CBDA-rich cannabis extract had more anti-cancer activity than an equivalent pure CBDA/CBD mixture, suggesting entourage effects from other plant constituents.
Why it matters
This study provides the first gene-level comparison of CBD and CBDA in colorectal cancer cells, revealing that whole-plant extracts may be more effective than purified compounds — supporting the entourage effect hypothesis.
The numbers in context
CBD IC50: HCT116 9.87±0.24 μM, HT29 17.11±2.52 μM, Caco-2 20.02±2.69 μM; CBDA minimal toxicity; extract > pure mixture for HCT116; CBD upregulated Wnt and Hippo signaling; increased caspase-3/7 activity
How the study worked
In vitro study testing CBD, CBDA, a CBDA-rich cannabis extract (CBDA:CBD ratio 20:1), and pure CBDA/CBD mixture on HCT116 and DLD1 colorectal cancer cell lines, measuring viability, clonogenic growth, and RNA sequencing for gene expression analysis.
What this study cannot tell us
In vitro cell line studies don't reflect tumor complexity; CBD concentrations used may not be achievable in vivo; only two cell lines tested for gene expression; CBDA-rich extract composition not fully characterized; no animal or human data.
How to read the evidence
Well-designed in vitro study with RNA sequencing providing mechanistic depth, but cell line results rarely translate directly to clinical benefit.
When this study was published
Published 2026; first gene expression comparison of CBD vs. CBDA in colorectal cancer.
The bigger picture
If CBD's anti-cancer effects translate to clinical settings, it could complement existing colorectal cancer treatments — and the entourage effect finding suggests whole-plant formulations may be worth pursuing over isolated compounds.
Questions still open
- Can these anti-cancer CBD concentrations be achieved in the human colon? Which compounds in the extract enhance anti-cancer activity beyond CBD and CBDA? Would CBD improve outcomes when combined with standard chemotherapy?
Common questions
Can CBD fight colorectal cancer?
Is CBDA also anti-cancer?
Read the original research
The differential effects of CBD and CBDA on viability and mRNA expression in colorectal cancer cells.
Journal of cannabis research, 8(1), 24
Citation
Heinzle, Christine; Geiger, Kathrin; Ertl, Reinhard; Brandtner, Eva Maria; Leiherer, Andreas; Gaenger, Stella; Schmidmayr, David; Drexel, Heinz; Muendlein, Axel. (2026). The differential effects of CBD and CBDA on viability and mRNA expression in colorectal cancer cells.. Journal of cannabis research, 8(1), 24. https://doi.org/10.1186/s42238-026-00391-2
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk